Patients may delay treating #HAE with on-demand injectables due to fear of needles, avoiding pain from treatment, and lack of privacy to perform an injection. On-demand treatment options that are noninvasive have the potential to help patients better follow the recommended treatment guidelines. (Source: Valerieva A, Jones D, van Kooten S, Malloy N, Heckmann M, Betschel S. Treatment of HAE attacks with anticipated future oral on-demand therapies as reported by patients. Abstract presented at: EAACI Annual Meeting, May 31-June 3, 2024. Valencia, Spain. Allergy. In Press.)
KalVista Pharmaceuticals, Inc.
生物技术研究
Cambridge,Massachusetts 7,305 位关注者
Creating a new generation of small molecule protease inhibitors for HAE and DME.
关于我们
KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our expertise to discover, develop and commercialize oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with sebetralstat, our first investigational product for hereditary angioedema (HAE), a rare genetic disease with debilitating attacks of tissue swelling that can be life threatening.
- 网站
-
https://kalvista.com
KalVista Pharmaceuticals, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge,Massachusetts
- 类型
- 上市公司
地点
-
主要
55 Cambridge Pkwy
US,Massachusetts,Cambridge,02142
KalVista Pharmaceuticals, Inc.员工
动态
-
On World Mental Health Day, we’re reminded that, for patients, anxiety often goes hand in hand with #HAE and its treatment. Having an attack management plan can help them feel prepared and make a difference in their wellbeing. Learn more about how you can support your patients’ needs: https://bit.ly/4f23cFn.
-
We are thrilled to be a part of the Hereditary Angioedema (HAE) community and hope to empower everyday lives. As we continue innovating, we anticipate many exciting updates! Be the first to hear. Sign up?at https://bit.ly/3NcXDaY. #HereditaryAngioedema
-
Hear what a real person living with #HereditaryAngioedema has to say about early on-demand treatment for HAE attacks. Visit our #MindtheHAEAttack website to gain insight into helping patients coordinate attack management: https://bit.ly/4dnRxPN
-
#TeamKalVista Chief Commercial Officer and Boston College alum Nicole Sweeny recently joined students at the BC Biotech Networking Night. Thank you to BC for hosting one of our own, and thank you to Nicole for sharing her passion, experience, and insights with the next generation of biotech! Learn more about our work, team, and open positions: https://bit.ly/3Y11caN
-
Our pioneering understanding of the kallikrein-kinin system has led to original science and groundbreaking advancements in targeting #HAE therapeutically. Learn more about our approach: https://bit.ly/4gBeaTE
-
We know that patients don’t always treat every HAE attack at the onset. Hear from allergist-immunologist Dr. Autumn Burnette on why patients delay treatment and what you can communicate to them about the importance of treating attacks early and consistently: https://bit.ly/3TGT6kV #MindtheHAEAttack #HereditaryAngioedema
-
Are you attending Cantor’s 2024 Global Healthcare Conference in NYC? Don’t miss our CEO Ben Palleiko speaking at a fireside chat during the event! Learn more about the conference here: https://bit.ly/3TpDkuG #TeamKalVista
-
Knowledge and creativity are essential traits for #TeamKalVista. Our diverse perspectives and collaborative spirit push boundaries, helping us make a difference in people’s lives. Explore our open positions: https://bit.ly/3XpuCgZ
-
We are deeply saddened to learn the conclusion of this tragedy involving Professor Marcus Maurer. The loss of Marcus creates a hole in our community that will be extraordinarily difficult to fill. We will miss him as a colleague, as well as his visionary approach, dedication to his work and passion for serving the community. We offer our most heartfelt condolences to Marcus’s family, friends and the entire angioedema and urticaria community.
Professor Marcus Maurer (1966–2024) We regret to announce the passing of Professor Marcus Maurer, a distinguished leader in dermatology and allergy, on 7 September 2024. His body was discovered by Italian mountain rescue teams near Lago Maggiore after he went missing following a hike in late July. Born on 22 May 1966 in Kaufbeuren, Germany, Professor Maurer was a renowned scientist and clinician whose contributions to allergy research have left a lasting legacy. He was Deputy Director of the Institute of Allergology at Charité - Universit?tsmedizin Berlin and Co-Director of Immunology and Allergology at the Fraunhofer ITMP. His work focused on mast cells, urticaria, mastocytosis, pruritus, and angioedema, advancing both scientific knowledge and clinical practice. Educated in Mainz and Berlin, with postdoctoral research at Harvard Medical School and Beth Israel Deaconess Hospital in Boston, Professor Maurer held board certifications in Dermatology and Allergology. He published over 850 articles and 55 books and chapters, leaving an indelible mark on allergy research and treatment. Professor Maurer was instrumental in GA2LEN - Global Allergy and Asthma Excellence Network, UCARE - Urticaria Centers of Reference and Excellence and ACARE - Angioedema Centers of Reference and Excellence, shaping the way these conditions are diagnosed and treated globally. His leadership and dedication bridged the gap between clinical practice and research, providing hope and improved care for countless patients. A visionary who united clinicians and scientists, Marcus was dedicated to inclusive collaboration and patient-centered care. His ability to inspire and mentor physicians at every career stage created a lasting impact, fostering a community dedicated to advancing the science of urticaria and angioedema. Our thoughts are with his family, and we express our deepest condolences. Marcus, you will be missed dearly as a colleague, coworker, and friend. Your legacy and the "Never give up" spirit you championed will continue to guide us. Your GA2LEN Family ??